29
/
en
AIzaSyAYiBZKx7MnpbEhh9jyipgxe19OcubqV5w
April 1, 2024
2135670
178559
2

nov 30, 2017 - FDA approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine- containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.

Added to timeline:

13 Nov 2018
0
0
313
Opioids and the FDA

Date:

nov 30, 2017
Now
~ 6 years and 3 months ago
PremiumAbout & FeedbackTermsPrivacy
logo
© 2022 Selected Technologies LLC – Morgan Hill, California